Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07496567 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Study acronym: TORRONTES
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 63 → 71 locationsv8
  2. Trial sites expanded: 56 → 63 locationsv7
  3. Trial sites expanded: 48 → 56 locationsv6
  4. Trial sites expanded: 9 → 48 locationsv5
  5. Recruitment opened
    • Trial sites expanded: 0 → 9 locations
    • Start date changed from estimate of Apr 30, 2026 to Apr 15, 2026
    v4
  6. 2 versions Re-verified since Mar 26, 2026, no change to tracked fieldsv2-v3
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Trial Details
NCT Number NCT07496567
Lead Sponsor EyeBiotech Ltd.
Conditions
(from sponsor)		 Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Related terms Choroidal Neovascularization, Macular Degeneration, Wet Macular Degeneration
Enrollment 960 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov